Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study

This study has been completed.
Sponsor:
Collaborator:
Novartis
Information provided by:
Daniels, Craig E., M.D.
ClinicalTrials.gov Identifier:
NCT00131274
First received: August 17, 2005
Last updated: October 4, 2005
Last verified: August 2005

August 17, 2005
October 4, 2005
April 2003
Not Provided
Progression defined as a greater than 10% decline in the forced vital capacity (FVC) or death
Progression defined as a greater than 10% decline in the forced vital capacity (FVC) or death.
Complete list of historical versions of study NCT00131274 on ClinicalTrials.gov Archive Site
  • Change from baseline in % predicted diffusing capacity of the lung for carbon monoxide (DLCO) at 96 weeks
  • Change from baseline in the resting arterial blood gas (ABG) assessment of A-a gradient at 96 weeks
  • Change in the number of meters walked in the 6 minute walk test at 96 weeks
  • Change from baseline in high-resolution computed tomography (HRCT) at 96 weeks
  • Change from baseline in the quality of life (QOL) assessments
  • Change in the modified C-reactive protein (CRP) score at 96 weeks
  • Mortality at 96 weeks
  • - Change from baseline in % predicted DLCO at 96 weeks
  • - Change from baseline in the resting ABG assessment of A-a gradient at 96 weeks
  • - Change in the number of meters walked in the 6 minute walk test at 96 weeks
  • - Change from baseline in HRCT at 96 weeks
  • - Change from baseline in the QOL assessments
  • - Change in the modified CRP score at 96 weeks
  • - Mortality at 96 weeks
Not Provided
Not Provided
 
Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study
A Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy (Gleevec Imatinib Mesylate) in Patients With Idiopathic Pulmonary Fibrosis

The purpose of the study is to evaluate the safety and efficacy of Gleevec (imatinib mesylate) in the treatment of idiopathic pulmonary fibrosis (IPF).

This is a multicenter, double-blind, parallel, placebo-controlled, randomized phase 2 study to evaluate the safety and efficacy of Gleevec (imatinib mesylate) in the treatment of Idiopathic Pulmonary Fibrosis (IPF). One-hundred- twenty patients will be enrolled in the trial in total. Subjects must have a diagnosis made by HRCT showing definite or probable IPF and clinical symptoms consistent with IPF with onset between 3 and 36 months prior to screening. Subjects will be randomly assigned to receive either Gleevec 600 mg orally or placebo, once per day for approximately 2 years. The primary efficacy will be progression defined as a greater than 10% decline in the forced vital capacity or death. Measures of safety will include all randomized patients who receive at least one dose of study medication. All adverse events and serious adverse events will be separately tabulated and mapped to a standard classification system and grouped by body system. Any serious adverse events that occur during the trial and 30 days after the end of therapy will be reported to the FDA within 24 hours and followed to outcome.

Interventional
Phase 2
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Educational/Counseling/Training
  • Idiopathic Pulmonary Fibrosis
  • Lung Disease
  • Pulmonary Fibrosis
Drug: Imatinib Mesylate (Gleevec)
Not Provided
Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR; Imatinib-IPF Study Investigators. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med. 2010 Mar 15;181(6):604-10. doi: 10.1164/rccm.200906-0964OC. Epub 2009 Dec 10.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
120
August 2007
Not Provided

Inclusion Criteria:

  • Clinical symptoms consistent with IPF with onset between 3 months and 36 months prior to screening
  • Worsening as demonstrated by any one of the following within the past year:

    1. >10% decrease in FVC % of predicted,
    2. Worsening chest x-ray or
    3. Worsening dyspnea at rest or on exertion
  • Age 20 –79 years of age. Subjects aged 20-50 must have diagnosis by either open or video-assisted thoracic surgery (VATS) lung biopsy
  • Diagnosis must be made by (HRCT) showing definite or probable IPF AND either of the following:

    1. Open or VATS lung biopsy showing definite or probable usual interstitial pneumonitis (UIP)
    2. Non-diagnostic transbronchial biopsy to exclude other conditions (including granulomatous disease and malignancies) AND abnormal pulmonary function tests (reduced FVC or decreased DLCO or impaired gas exchange with rest or exercise) AND 2 of the following:
    1. Age >50 years
    2. Insidious onset of otherwise unexplained dyspnea or exertion
    3. Bibasilar, inspiratory crackles on examination
  • FVC> 55% of predicted value at baseline
  • DLCO > 35% of predicted value at screening
  • PaO2 >60 mmHg (sea level) or 55 mmHg (altitude) at rest on room air
  • Able to understand and willing to provide informed consent prior to any study procedures

Exclusion Criteria:

  • History of clinically significant environmental exposure known to cause pulmonary fibrosis
  • Diagnosis of connective tissue disease
  • FEV1/FVC ratio < 0.6 at screening (post-bronchodilator)
  • Residual volume > 120% predicted at screening
  • Evidence of active infection
  • Any condition other than IPF, which, in the opinion of the site principal investigator, is likely to result in the death of the patient within the next year
  • History of unstable or deteriorating cardiac or neurologic disease
  • Women with child bearing potential
  • Current treatment with corticosteroids, cytoxan, azathioprine, colchicines, pirfenidone, interferon gamma or beta, anti-tumor necrosis factor therapy or with endothelin receptor blockers.
Both
20 Years to 79 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00131274
CST1571E2401
Not Provided
Not Provided
Daniels, Craig E., M.D.
Novartis
Principal Investigator: Craig E Daniels, MD Mayo Clinic
Principal Investigator: Joseph Lasky, MD Tulane University
Daniels, Craig E., M.D.
August 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP